Pick Your Community: | Hopkins | Muhlenberg | Daviess | Christian | Fayette | Henderson | Lakes | McCracken | Warren | Webster

FDA Approves New Drug for Advanced Prostate Cancer

fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

© Copyright 2014 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story by using one of the social media links below.

In Other News...

PACS Bus Wrecks Along Hopkinsville Street

GREENVILLE, Ky. (8/20/14) ― Greenville Police Department responded to a single-vehicle collision at 7:38 a.m., today,… Read More

Cash Mob Visits Green Leaf Boutique in Central City

CENTRAL CITY, Ky. (8/20/14) — There was a Greater Muhlenberg Chamber of Commerce 'Cash Mob' early this morning at Green… Read More

Most Read This Week (Site-Wide)

August 17, 2014 4257

Greenville Police Conducting Traffic…

in Top Stories by Wes Miller
August 18, 2014 3873

Man Injured in Early Morning WKP Accident

in Top Stories by Rita Dukes Smith, SurfKY News Director
August 18, 2014 3583

Owensboro Board of Commissioners…

in News by Beth Cecil
August 20, 2014 3421

Park Avenue Trespass Call Leads to…

in Top Stories by Madisonville Police Department
August 18, 2014 3403

Unlawful Solicitation

in News by Sgt. J.D. Winkler

Most Read Stories from Hopkins County

August 20, 2014 3421

Park Avenue Trespass Call Leads to…

in Top Stories by Madisonville Police Department
August 18, 2014 2589

Madisonville Man Charged for Shoplifting,…

in Top Stories by Madisonville Police Department
August 20, 2014 1421

Dawson Springs Woman Arrested for Driving…

in Top Stories by SurfKY News
August 18, 2014 1398

Madisonville Firefighters Recognized for…

in Top Stories by Rita Dukes Smith, SurfKY News Director
August 20, 2014 1114

Theft at Pennyrile Park Apartments Leads…

in Top Stories by Madisonville Police Department

Most Read Stories from Owensboro

August 18, 2014 3583

Owensboro Board of Commissioners…

in News by Beth Cecil
August 18, 2014 3403

Unlawful Solicitation

in News by Sgt. J.D. Winkler
August 18, 2014 3328

RiverArtes Opening at OMFA

in News by Owensboro Museum of Fine Art
August 19, 2014 2788

Free Arthritis Exercise Program will be…

in News by Woody Maglinger
August 19, 2014 2629

Municipal Art Collection on Exhibit at…

in News by Mary Bryan Hood

Most Read Stories from Muhlenberg County

August 17, 2014 4257

Greenville Police Conducting Traffic…

in Top Stories by Wes Miller
August 18, 2014 3873

Man Injured in Early Morning WKP Accident

in Top Stories by Rita Dukes Smith, SurfKY News Director
August 18, 2014 3302

Luke's Flea Market Vendors' Home Away…

in Top Stories by Charles W. Riley II, SurfKY News
August 18, 2014 3128

'How Dry I Was'

in Top Stories by Rita Dukes Smith, SurfKY News Director
August 19, 2014 2347

'Another One Bites the 'Duct'

in Top Stories by Paul McRee, SurfKY News

SurfKY News Group, Inc. Central Office & Printing Division
1125 Nebo Rd.  •  Madisonville, KY 42431  •  270.452.2249 (fax)
Main Number: 270.452.2727 (phone)  •  Printing Division Direct Line: 270.821.8600 (phone)

SurfKY Owensboro News Bureau
920 Frederica St. / Suite 210  •  Owensboro, KY 42301  •  270.683-8060 (phone)


Contact a member of our staff: www.surfky.com/contact
Copyright © 2014 SurfKY News Group, Inc.  •  Terms of Use  •  Site Map

social 03social 04social 22social 21social 06